SXTC — China SXT Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1723980 ·
China
Last close
$0.34
Market Cap
$453.9K
52W High
$83760.00
52W Low
$0.31
ADV30
7,815,243
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | 34,754,574 | 28,175,865 | 5,047,152 |
| Sep 2025 | — | — | — | — | 26,353,283 | 21,166,494 | 6,119,748 |
| Mar 2025 | — | — | — | — | 21,663,508 | 18,099,019 | 6,223,746 |
| Sep 2024 | — | — | — | — | 29,990,005 | — | 19,808,210 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-34,220,402
Inventory
$777,059
Receivables
$3,232,358
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,138,052
EBITDA
$-7,049,265
Free Cash Flow
$-4,736,071
Enterprise Value
$-26,168,870
Total Cash
$28,320,836
Total Debt
$1,120,986
Shares Out
1,321,418
Trailing EPS
$-730.40
Book Value
$2480.58
ROE
-27.5%
ROA
-15.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,138,052 | -7,122,933 | -6,205,085 | 34,754,574 | 5,047,152 | 29,707,422 | -4,017,456 |
| Mar 2025 | 1,740,907 | -2,680,479 | -3,303,652 | 21,663,508 | 6,223,746 | 15,439,762 | -2,345,333 |
| Mar 2024 | 1,928,497 | -2,515,217 | -3,098,532 | 23,127,057 | 9,196,611 | 13,930,446 | -1,928,053 |
| Mar 2023 | 1,971,679 | -5,607,509 | -5,934,772 | 29,554,056 | 14,862,761 | 14,691,295 | -80,757 |
| Mar 2022 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals Plc | $538.9K | $0.52 | — |
| CYTOF | Altamira Therapeutics Ltd. | $371.8K | $0.07 | — |
| CNBX | CNBX Pharmaceuticals Inc. | $321.2K | $0.00 | — |
| ZVSA | ZyVersa Therapeutics, Inc. | $647.7K | $0.08 | — |
| RGBPP | Regen BioPharma Inc | $238.1K | $0.00 | — |
News headlines (Yahoo Finance, 1h cache)
China SXT Pharmaceuticals Announces $12 Million Registered Direct Offering With Significant Dilution Potential
2026-10-08 14:44 · Yahoo
China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering
2026-10-08 13:22 · Yahoo
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
2026-08-05 13:00 · Yahoo
BC-Most Active Stocks
2026-10-09 14:30 · Yahoo
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
2026-07-24 21:30 · Yahoo
China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
2026-07-23 12:45 · Yahoo
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
2026-03-23 13:00 · Yahoo
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN
2026-01-15 14:00 · Yahoo
Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
2026-01-13 22:00 · Yahoo
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
2026-01-09 19:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.